(Re)Appraising Remission in Ulcerative Colitis-Reference-Cited by-同舟云学术

(Re)Appraising Remission in Ulcerative Colitis

Published:2022-08-02 Issue: Volume: Page:
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Sood Ajit¹^ORCID,Singh Arshdeep¹^ORCID,Mahajan Ramit¹^ORCID,Midha Vandana²,Bernstein Charles N³,Rubin David T⁴^ORCID

Affiliation:

1. Department of Gastroenterology, Dayanand Medical College and Hospital , Ludhiana, Punjab , India

2. Department of Internal Medicine, Dayanand Medical College and Hospital , Ludhiana, Punjab , India

3. IBD Clinical and Research Centre and Section of Gastroenterology, Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba , Canada

4. Inflammatory Bowel Disease Center, University of Chicago Medicine , Chicago, IL , USA

Abstract

Abstract As the therapeutic targets in ulcerative colitis (UC) shift from control of symptoms to mucosal healing and prevention of disease complications like disability, colectomy, and cancer, the definition of remission has evolved. The current definition of clinical remission is variable and is determined by the clinical context in which it is being used. This results in skepticism and uncertainty about the true meaning of the term “clinical remission.” In this review, the authors reexamine the definition of clinical remission and propose a novel approach to define remission in UC.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izac170/45214566/izac170.pdf

Reference106 articles.

1. Ulcerative colitis;Ungaro;Lancet Lond Engl.,2017

2. Ulcerative colitis: current and emerging treatment strategies;Kayal;J Clin Med.,2019

3. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set;Ma;Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.,2018

4. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol.,2015

5. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD;Turner;Gastroenterology.,2021